Authors
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
Pelabresib in MPNs: Immune Profiles of Responders vs. Non-respondersPanelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).
Latest:
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer SurvivorshipThe lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.
Latest:
Unmet Needs and Future Directions for GPRC5D Bispecific TherapyPanelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
Latest:
Treatment Considerations for Bispecific Antibodies and Unmet Needs in MMThe expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple MyelomaCancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Latest:
Determining Suitable Radioligand Therapy Use in Neuroendocrine TumorsOncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.
Latest:
Metastatic CSPC: Future Directions in CareBefore closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
Latest:
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerOriginal research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
Latest:
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLCThe expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Evaluation and Management of Testicular Cancer After Late RelapseThe clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Emerging Data and Future Directions in UCExperts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
Latest:
Expert Commentary on the Product Profile of TepotinibIn an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Importance of a Multidisciplinary Team at a Hispanic Breast Cancer ClinicThe Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
